Biopharmaceutical Contract Manufacturing Market is estimated to be worth USD 13.9 billion in 2030

B2B Forum › Category: Marketing, Advertising and PR › Biopharmaceutical Contract Manufacturing Market is estimated to be worth USD 13.9 billion in 2030

0 Vote Up Vote Down

Stella Wilson asked 3 years ago

Outsourcing has become a popular trend among biopharmaceutical developers, allowing them to leverage the expertise / larger production capacities of CMOs / CDMOs and achieve significant cost and time related advantages
Roots Analysis is pleased to announce the publication of its recent study, titled, “Biopharma Contract Manufacturing Market, 2021-2030.”
The report features an extensive study on the contract service providers within the biopharmaceutical industry. The study features in-depth analysis, highlighting the capabilities of a diverse set of biopharmaceutical CMOs and CDMOs. Amongst other elements, the report includes:

A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters.
Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing, and packaging of biologics.
A detailed discussion on the key enablers in this domain, including certain niche product classes, which are likely to have a significant impact on the growth of the contract services market.
A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.
A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.
An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics.
A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity.
An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects.
An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions.
A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.
A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.
A discussion on affiliated trends, key drivers, and challenges, under a comprehensive SWOT framework.
A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers.

Request for Customization: https://www.rootsanalysis.com/reports/250/request-customization.html
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Commonly Outsourced Business Operations

Active Pharmaceutical Ingredients (API)
Finished Dosage Formulations (FDF)

Types of Expression System

Mammalian
Microbial
Others

Company Size

Small
Mid-Sized
Large and Very Large

Scale of Operation

Preclinical
Clinical
Commercial

Key Geographical Region

North America
Europe
Asia-Pacific
Rest of the World

The report also features detailed transcripts of discussions held with the following experts:

Astrid Brammer, Senior Manager Business Development, Richter-Helm Mathias Schmidt (Chief Executive Officer, ArmaGen)
Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie
Christian Bailly, Director of CDMO, Pierre Fabre
Claire Otjes, Assistant Marketing Manager, Batavia Biosciences
David C Cunningham, Director Corporate Development, Goodwin Biotechnology
Dietmar Katinger, Chief Executive Officer, Polymun Scientific
Denis Angioletti, Chief Commercial Officer, Cerbios-Pharma
Jeffrey Hung, Chief Commercial Officer, Vigene Biosciences
Kevin Daley, Director Pharmaceuticals, Novasep
Mark Wright, Site Head, Grangemouth, Piramal Healthcare
Nicolas Grandchamp, R&D Leader, GEG Tech
Raquel Fortunato, Chief Executive Officer, GenIbet Biopharmaceuticals
Sebastian Schuck, Head of Business Development, Wacker Biotech
Stephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies
Tatjana Buchholz, Marketing Manager, PlasmidFactory and Marco Schmeer, Project Manager, PlasmidFactory
Tim Oldham, Chief Executive Officer, Cell Therapies